Page 8 - reflections_newsletter_June8_2022
P. 8
REFLECTIONS dae mia
Dyslipidaemia Global Newsletter #2
aim ead
Dyslipi
major role in protection. This confirms previous observations from a number of studies on the protective effect of high adherenceDytsolipi
lipid-lowering treatment.
Thus, regarding improvement of adherence, a single-pill combination of statin and ezetimibe may improve CV protection in people
that require two-drug lipid lowering treatment.
Hazard ratios and 95% confidence intervals for the composite outcome (CV mortality or CV hospitalization) with low, intermediate,
and high adherence to lipid-lowering drugs, and drug treatment strategy (i.e. single-pill vs. two-pill combination of a statin and
ezetimibe).
TABLE OF CONTENTS Learn more at: www.serviercardiomedicalhub.com
